Trial Profile
Safety and efficacy of Nivolumab in patients with advanced malignant mesothelioma : An Expanded Access Program
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 18 Jun 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Malignant-mesothelioma
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 18 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology